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Abstract
We propose a stochastic individual-based model of the progression of atrial fibrillation (AF). The model
operates at patient level over a lifetime and is based on elements of the physiology and biophysics of AF, making
contact with existing mechanistic models. The outputs of the model are times when the patient is in normal
rhythm and AF, and we carry out a population-level analysis of the statistics of disease progression. While
the model is stylised at present and not directly predictive, future improvements are proposed to tighten the
gap between existing mechanistic models of AF, and epidemiological data, with a view towards model-based
personalised medicine.
Keywords: atrial fibrillation, stochastic individual-based model, uncertainty quantification
1 Introduction
Atrial Fibrillation (AF) is an electrical heart disease
characterised by irregular heart rhythm and absence of
organised atrial activity, with a prevalence of 1 − 2%
in the UK [1]. Incidence and progression of AF in-
creases with age [1], and is correlated with hyper-
tension, diabetes and other cardiovascular conditions
[2, 3, 4]. Furthermore, AF significantly increases risk
of stroke [5, 6, 7]; thus, the importance of understand-
ing this disease and of predicting its progression is
undisputed. Aside from improved monitoring of pa-
tients and clinical intervention, computational mod-
elling is becoming increasingly valuable in the medi-
cal sciences, in particular with a view towards person-
alised medicine [8]. A natural question is then to as-
sess what is the most appropriate time and space scale
over which to construct models of AF. Biophysically
detailed models of cardiac cells and tissues can provide
insights into the mechanisms that initiate and sustain
AF [9], whereas population-level models, parametrised
by available epidemiological data enable treatment
pathways to be evaluated [10]. The most appropriate
model will of course depend on the specific problem in
hand.
Biophysically detailed models of cardiac cells and
tissue are based on the physical laws governing the
electro-mechanics of the heart. Simulating these mod-
els however is computationally expensive, and so only
time scales of a few heartbeats in a single patient are
accessible [8]. This constraint prevents a bottom-up
simulation of progression of the disease in a single pa-
tient at a time scale longer than a few minutes, and
so these models are not suitable for complete study of
the self-reinforcing effect of AF (‘AF begets AF’ [11])
which occurs over days, weeks, and years. Construct-
ing predictive models for the life-time progression of
AF in individual patients based on the underlying bio-
physics is therefore difficult given current computa-
tional resources.
Population-level models can capture long time
scales, but they require epidemiological data as an
input to determine model parameters. Clinical data
are available at medium time scales of several days,
but these data are sparely sampled, and mostly col-
lected from patients with implanted monitoring de-
vices. These patients are more likely to have other
cardiac-related co-morbidities, and so the sample is
biased. In addition, the storage capacities of devices
limit the temporal resolution of the data. To our
knowledge, on a population-level, a quantitative model
describing the progression of the disease at a long time
scale is not yet available, and so the gap between acute
mechanistic approaches and modelling on time scales
of the human lifetime remains.
The aim of the present study is to make progress
towards closing this gap and linking the small scale
biophysical models with epidemiological models at a
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population level. Ultimately, one may hope that one
day fully developed multi-scale models will be avail-
able, capable of predicting the progression of a given
patient through the stages of AF over a time scale of
years and starting from personalised parameters (e.g
extent of atrial fibrosis obtained from cardiac imag-
ing). Such models, if they can be constructed, would
provide a key step towards computer-based predictive
personalised medicine, and the ability to more accu-
rately design individual treatment plans and to predict
the cost-effectiveness of new interventions population-
wide.
To work towards this long-term goal we propose
a coarse-grained patient-level stochastic model, based
on some elements of the current understanding of the
mechanisms that spontaneously initiate, sustain, and
terminate AF. The finest scale described by the model
is the status of a patient with respect to the disease,
i.e. a patient can at any one time be in an episode of
AF, or in sinus rhythm (SR). The switching between
these states is governed by two rates, describing initi-
ation and termination of episodes respectively. Both
of these rates are patient-specific in the model, and
reflect genetic disposition, age and individual patient
history. Most crucially, the model describes the ef-
fects of episode-based remodelling of the heart, mak-
ing future episodes more likely. To capture this AF-
begets-AF effect the model retains a transient mem-
ory of earlier episodes, and these affect the initiation
and termination rates of later episodes. Many of these
processes and the parameters describing them are—
in principle—linked to the underlying biophysics. We
stress clearly that establishing this link quantitatively
is of course a major enterprise, and not within the
scope of the present work. The spirit of our paper is
very much to make a first step in this direction.
The remainder of the paper is structured as follows:
In the next section we describe some of the main fea-
tures of AF, both from the biophysical microscopic
perspective and from the long-term epidemiological
view. Our account is not comprehensive; we focus
on features relevant to our modelling approach. In
Section 3 we then present the actual mechanics of the
model with a detailed quantitative description avail-
able in the Appendix for clarity. The outcome of our
simulations is then described in Section 4, before we
summarise our model and discuss its potentials and
limitations.
2 Main features of AF relevant to the
model
2.1 Biophysical processes
We briefly summarise the biophysical phenomena con-
tributing to the key processes described by the model:
initiation and termination of episodes of AF, ignoring
external interventions such as pacemakers, cardiover-
sion, or effects of medication. The likelihood of initia-
tion and termination of AF in the model is dependent
upon remodelling of structural and and functional el-
ements of the heart, which occur over multiple time
scales [13, 14, 15].
2.1.1 Initiation of episodes of AF
The transition from sinus rhythm (SR) to AF is char-
acterised by a combination of a triggering event and
an existing vulnerability of the atria to such trig-
gers [16]. This combination results in self-sustaining
rotating waves of electrical activation, which act to
suppress normal beats arising from the heart’s natu-
ral pacemaker. Examples of triggering events are a
rapid increase of the atrial rate, and ectopic electrical
beats within the atria [17, 18]. Increased vulnerabil-
ity or triggers can be due to structural abnormalities
in the atria such as fibrosis, hypertrophy or gap junc-
tional lateralisation [19, 20, 21], and specific electrical
changes, which transiently modify the electrical be-
haviour of cardiac cells [3, 11, 16, 22, 23, 24].
We adopted a coarse-grained picture of these de-
tailed electrophysiological processes underpinning the
initiation of episodes of AF. In our model the physio-
logical state of the atria of a patient is described by a
binary state: the patient can either be in AF or SR. In
our approach, we separate triggering events from the
vulnerability of the atria. Trigger events are seen as
external to the model, so we do not include changes in
patient-specific behaviour or physiology affecting the
frequency of triggers. For simplicity, we assume that
triggering events occur at a constant rate, throughout
the life time of a patient. The time between two trig-
ger events is random and exponentially distributed. In
our model the vulnerability then describes the prob-
ability that a given trigger event leads to an episode
of AF: the higher the vulnerability of the atria, the
greater the probability that a triggering event induces
an AF episode.
We consider three factors contributing to a patient’s
vulnerability: (i) a genetic predisposition, (ii) an age
and co-morbidity related factor, and (iii) previous his-
tory of the patient. These factors were succinctly sum-
marised by Heijman et al. [12]. Based on this existing
work we illustrate the different components contribut-
ing to vulnerability in Fig. 1. Genetic pre-disposition
is constant and does not depend on age. The contribu-
tion related to age and co-morbidities increases with
time; we assume implicit correlation of age to other co-
morbidities such as pulmonary hypertension, hyper-
trophy etc, and do not therefore consider independent
effects of specific co-morbidities in the present study.
The third element—previous history of the patient—
models the memory effects of AF. The vulnerability of
a patient at any one time depends on the time spent
in AF previously and on the number of episodes the
individual has experienced so far, and when these oc-
curred.
Factors (ii) and (iii) capture the effects of physiolog-
ical remodelling: Structural and electrical properties
of the atria are modulated by risk factors including
ageing and previous history of AF [3, 16]. All factors
are patient-specific: different patients in the simula-
tion can, in principle, have distinct parameter settings.
2.1.2 Recovery
The biophysical mechanisms leading to spontaneous
termination of an episode of AF are much less studied
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Figure 1: A framework of AF initiation, maintenance and progression, modified from [12]. AF onset is dependent
on vulnerability and triggers. Vulnerability is dependent on a constant genetic predisposition, time-varying age/co-
morbidity-related remodelling and AF-related remodelling dependent on AF history. An increase in vulnerability
may allow initiation of AF episodes upon a trigger event occurring; over time, some patients progress on to
paroxysmal, persistent and permanent AF as their AF vulnerability increases. Note the timescale for AF triggers
and episodes is distinct from the lower axis and is expanded for visualisation.
and understood than those leading to the initiation of
an episode. Our formulation is based on the hypothe-
sis that the factors contributing to the rate with which
episodes terminate are similar to those contributing to
activation. Any factor leading to an increase in the ini-
tiation rate is taken to cause a reduction in the termi-
nation rate. Specifically, we assume one contributing
factor reflecting age and co-morbidities. This term in
the recovery rate decays (exponentially) as the patient
ages, and does not depend on previous history of AF
progression. A second component depends on previ-
ous history: the propensity to recover from an episode
of AF is reduced by time spent previously in the AF
state.
2.1.3 Acute clustering
Recurrence of an AF episode shortly after an exist-
ing episode has been observed in clinical studies [25].
Kaemmerer et al [26] suggest that the likelihood of re-
currence is highest immediately after termination and
decreases over time, and that a long episode is likely to
be followed by multiple shorter episodes immediately
after. In order to capture this effect we assume that ac-
tivation rate is increased immediately after an episode
and exponentially decays to baseline, which is inde-
pendent of AF history. We assume the recovery rate
follows a similar trend; however we already assumed
that the history component of AF recovery rate tran-
siently decreases as time in an episode increases. To
capture the effect that long episodes are immediately
followed by short episodes, we thus assume the recov-
ery rate ‘overshoots’ above baseline immediately after
an episode terminates, then decays back to baseline.
2.2 Progressive stages of AF
Three stages have been broadly defined clinically in the
progression of AF: (i) paroxysmal AF, (ii) persistent
AF, and (iii) permanent AF. This is briefly illustrated
in the schematic of Fig. 1).
In paroxysmal AF, a fibrillation episode has a typ-
ical duration of minutes or hours, lasting up to 7
days, with episodes spontaneously terminating. Inter-
episode times can vary greatly from days to months
[27], and inter-episode times will often reduce as the
condition progresses, due to physiological remodelling
[11, 24, 28]. The next stage, persistent AF, is indi-
cated when the patient has AF episodes lasting 7 days
or more, which do not self terminate and require med-
ical intervention such as cardioversion. A patient is in
permanent AF when the episodes have continued for
more than 1 year; typically interventions to terminate
the fibrillation will fail.
We stress that although these stages are used to se-
lect appropriate treatment strategies, it is difficult to
diagnose the stage any one AF patient is in clinically.
Any such assessment is therefore approximate in prac-
tice.
2.3 Model Outline
Our model describes a patient as either in AF or in
sinus rhythm at any one time. A patient trajectory is
therefore a series of points in time at which episodes
begin and end. The starting point of the simulation is
the birth of the patient, and all episodes are ‘detected’
in the simulation. A real patient would not necessar-
ily be diagnosed to have paroxysmal AF upon initial
occurrence of an AF episode; thus we use the follow-
ing classification in our simulations. (i) A patient is
considered to progress to paroxysmal AF immediately
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Figure 2: Illustration of the main mechanics of the model. Vulnerability of AF due to ageing, Vage, increases
according to a sigmoid function, and age-based recovery rate R0 decreases exponentially. A healthy patient
triggers an AF episodes with rate V (t)/τ and terminates an AF episode with rate R(t). In AF, episode-based
remodelling Vepi transiently increases vulnerability at a rate α and decreases the total recovery rate R at rate µ.
When an episode terminates, the recovery rate ‘boosts’ above baseline by a factor of B. Back in sinus rhythm,
Vepi decays to zero with rate β and Repi decays with rate ν back to the age-based baseline R0.
following an episode of at least 14.4 minutes (1% of
a day). (ii) They are said to be in persistent AF fol-
lowing an episode lasting 7 days, and (iii) progress to
permanent AF from the point in time at which they
enter an AF episode which continues until the end of
the simulation at age 100 years, without return to si-
nus rhythm.
3 Description of the model
3.1 General setup
The model describes the trajectory of individual pa-
tients throughout their life time. Patients can be sim-
ulated individually, and they do not interact. Time in
the model is continuous, and at each point in time t a
patient is characterised by three attributes, their AF
status S(t), their vulnerability, V (t), and their recov-
ery rate R(t).
The AF status indicates if the patient is in AF at
time t; if so we write S(t) = 1, otherwise S(t) = 0.
As far as the occurrence of AF episodes is concerned a
patient trajectory is fully characterised by the values
S(t) for all times t. Simulations start at age of zero
years, this is labelled t = 0. They end at age 100 years
(t = 100).
The behaviour of S(t) is determined by the activa-
tion and termination rates of AF episodes. If a pa-
tient is in sinus rhythm at time t they can begin a
new AF episode, this occurs with rate V (t)/τ in our
simulation. The prefactor τ−1 indicates the frequency
of trigger events. As described in earlier sections the
initiation of episodes of AF occurs based on trigger-
ing events combined with existing vulnerability of the
patient. The factor τ−1 reflects the trigger, and V (t)
stands for the vulnerability.
If a patient is in an episode of AF at time t (S(t) =
1) they may return to sinus rhythm. This occurs with
rate R(t).
Mathematically speaking the model describes a bi-
nary process, in which S(t) flips between the two states
S = 0 and S = 1 at random times. The statistics of
these transitions is governed by the time-dependent
rates V (t)/τ and R(t), both of which have units of
inverse years. The underlying biophysical elements of
AF initiation and termination we wish to describe (see
Sec. 2.1) are encapsulated in the detailed mathemat-
ical forms of these rates. It is important to keep in
mind that these depend on the prior history of the
patient, and so V (t) and R(t) are not set quantities,
but random variables themselves. We will describe
the mathematical forms of these rates next. In doing
this we will first define the general mathematics, and
not specify the numerical values of the various model
parameters we are about to introduce. These will be
discussed further below.
3.2 Vulnerability V (t)
The vulnerability V (t) is made up of three compo-
nents; genetic predisposition, age and co-morbidity re-
lated vulnerability, and episode-induced vulnerability
[12]. We write this as
Vt = V0 + Vage + Vepi. (1)
The quantity V0 is the vulnerability associated with ge-
netic predisposition, it is time-invariant and may vary
from patient to patient. The second component, Vage,
is the vulnerability associated with the age and with
co-morbidities that may develop with time. In the
present study we do not model co-morbidities inde-
pendently or explicitly, and simply assume that Vage
depends primarily on age (i.e. other co-morbidities are
implicitly correlated with age), but not on the prior
AF-history of the subject. This type of vulnerability
increases with time. More specifically we assume a
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sigmoidal function for the functional form of Vage,
Vage =
V1
1 + exp
(
− t−tctd
) . (2)
Age/co-morbidity-dependent vulnerability is low in
the initial phases of a subject’s trajectory (i.e. t ≈ 0),
and it then increases to plateau, V1, at higher ages.
The parameter tc describes the location of the turning
point in this evolution, and td characterises the width
of the sigmoid, i.e. the duration of the transition be-
tween low vulnerability and the final plateau.
It remains to define Vepi as the vulnerability associ-
ated with acute remodelling. The following piecewise
process is adopted to model Vepi. When the patient
is not in AF, i.e. at times when S(t) = 0, we assume
that Vepi decays exponentially with rate β,
d
dt
Vepi(t) = −βVepi(t), when S(t) = 0. (3)
When a patient is in AF (i.e., when S(t) = 1), we
assume that the vulnerability grows exponentially in
time limited by a maximum vulnerability of Vmax.
Mathematically we write
d
dt
Vepi(t) = α [Vmax − Vepi(t)] , when S(t) = 1. (4)
The model parameters α and β are the relaxation rates
of Vepi back to 0 when S(t) = 0, or to maximum value
when S(t) = 1.
We further assert that the vulnerability V (t) is con-
tinuous: after a random switching event into AF or
out of AF, the initial condition of Vepi(t) in the fol-
lowing segment is set as the final value of Vepi(t) right
before the switching event. A schematic diagram of
the evolution of V (t) is presented in Fig. 2.
3.3 Recovery rate R(t)
Next, we define the recovery rate R(t) to consist of
two components:
Rt := Rage(t) +Repi(t). (5)
The variable Rage(t) stands for a naturally declining
ability to recover from an established episode. The
decline is due to age, and it is taken to be exponential
with rate λ,
Rage(t) := R0e
−λt. (6)
The second component, Repi, is the history-dependent
recovery rate, which is known to be a function of pre-
ceding episodes of AF [11]. Similar to the above proce-
dure for the vulnerability we define a piecewise process
for Repi. When the subject is not in AF, we assume
d
dt
Repi = −νRepi(t) when S(t) = 0, (7)
which describes the recovery from future episodes of
AF, and indicates an exponential decay of Repi with
rate ν during times the patient is in SR.
When the patient is in the AF state (S(t) = 1) we
assume that the total recovery rate, R(t) = Rage(t) +
Repi(t) falls exponentially with rate µ
d
dt
R(t) = −µR(t), when S(t) = 1. (8)
This different formulation is intended to capture the
short term remodelling that takes place during an
episode of AF, and acts to reduce the likelihood of ter-
mination. Crucially we assume µ > λ, i.e. the drop in
total recovery rate during AF is quicker than the drop
of Rage(t) when the subject is in sinus rhythm. Typ-
ically the total recovery rate R(t) will fall below the
baseline rate Rage(t), hence Repi(t) = R(t) − Rage(t)
formally turns negative; we comment on this below.
The dynamics illustrated in Fig. 2.
In order to capture the clustering of several short
episodes frequently observed clinically after a long AF
episode, we introduce an additional ‘boost’ term into
the dynamics of the recovery rate. Specifically we use
the following procedure when an episode of AF ter-
minates. Say the termination time is t. Prior to this
moment the patient will have been in AF, and so R(t)
is governed by Eq.(8). The age-related contribution is
Rage(t) = R0e
−λt, see Eq.(6). Together these equa-
tions define Repi = R − Rage just before the end of
the episode at t. After a long episode of AF this net
rate Repi will often be negative. To capture the clus-
tering we assume that immediately after the end of
an episode the total recovery rate R(t) overshoots and
exceeds the natural background Rage(t). In order to
implement this we introduce an instantaneous boost
at the end of an episode: we change the sign of Repi(t)
and we allow for an additional factor B > 0 in its mag-
nitude: Repi → −B × Repi. This is only implemented
if Repi(t) < 0 just before the end of the episode, other-
wise no reflection or boost are applied. We note that
negative rates of Repi do not obviously have a direct
meaning in isolation. In our model only the total re-
covery rate R = Rage + Repi, has a direct biological
interpretation. This rate is always positive.
The different features of the dynamics are illustrated
in Fig. 2, where we also show stylised possible time
courses of the vulnerability and recovery rate.
3.4 Implementation
The model constitutes a continuous-time stochastic
process with discrete and continuous variables. During
episodes and during times of sinus rhythm the rates
R(t) and V (t) evolve deterministically according the
dynamics specified by the ordinary differential equa-
tions above. The switching dynamics between S = 0
and S = 1 (SR and AF) is stochastic and governed
by these rates. The transition rates evolve determin-
istically over time conditional on the current state of
the subject. The model can be implemented relatively
straightforwardly using a modified Gillespie algorithm
[29, 30] to account for the time-dependent rates gov-
erning the statistics of the switching events into and
out of AF. This is discussed further in the Appendix.
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Parameter Description Value Unit Comment/Reference
1/τ Triggering rate 1 1/year Basic simulation time unit
V0 Gene. predis. vul. 10−5 n/a Set arbitrarily small
V1 Max. age/disease vulnerability 2920 n/a Paroxysmal AF patients have up to 8 episodes/day [31]
Vmax Max. episode vulnerability 2× v1 n/a AF doubles VW in tissue [32]
tc Age/disease transition time 70 years Mean incidence rate [33, Table 1]
td Age/disease transition width 3 n/a Gives range ±10 years
α Episode vul. saturation rate 52 1/yr AERP stabilises after one week [34]
β Episode vul. relaxation rate 182.5 1/yr AERP recovers after two days [35]
R0 Peak recovery rate (r.r.) (of new born) 0.5 second Min possible period of AF
λ Nat. degradation rate of r.r. 1.2/50 ∗ log(840) Set so that patient has 14.4 min episode at age 50
µ Degradation rate of total r.r. in AF α Follows α
ν Relaxing rate of epi. r.r. when Healthy β Follows β
B Boost factor of r.r. post AF 1 n/a 1: overshoot×1; 0: no o/s
Table 1: The parameter set used in model simulations. Where possible, parameters were estimated from literature;
certain parameters were set to reproduce incidence behaviours from epidemiological studies.
3.5 Model parameters
The parameter set used in the present study is listed in
Table 1 and discussed below. We stress that these are
not definitive population-representative values, and
that further exploration of the parameter space is nec-
essary.
The external triggering rate 1/τ scales the vulner-
ability V (t) and has units of inverse time. We here
use τ = 1/yr, and use years as our unit of time. In
the following we will occasionally omit units in activa-
tion and recovery rates, as they are always understood
to be per year. The numerical values of the different
components of V (t) can then be set individually, as
shown in Table 1. The parameters V0, V1 and Vmax
are dimensionless quantities. We are focused on inves-
tigating effects of natural history and of AF-dependent
remodelling, and thus set the vulnerability due to ge-
netic predisposition V0 to be very small at 10
−5. Age-
ing is a key predictor of AF vulnerability [36], with in-
cidence and prevalence rates increasing with age. For
the vulnerability due to ageing/co-morbidity, Vage(t),
we set the maximum value V1 as 365×8 = 2920 on the
basis of Hoffmann et al [31] who reported a median of
8 episodes per day in a patient cohort with paroxysmal
AF. For vulnerability due to AF history Vepi, we cite
a recent computational study from Colman et al [32],
who predicted that chronic AF doubles the vulnerable
time window (in which the atria is susceptible to for-
mation of AF-inducing re-entrant circuits) compared
to baseline; we take this to assume that Vmax = 2×V1.
To identify the parameters of the sigmoid curve de-
scribing increase in vulnerability due to ageing, we
looked at the incidence rates of AF in several pop-
ulation studies [33, 37, 38, 39] and chose parameters
tc = 70 and td = 3, representing a sigmoid centred
at 70 years of age, with a range of approximately 10
years.
The saturation and recovery rates for episode-
related vulnerability were estimated from a series
of experimental studies establishing the existence of
AF-induced AF over timescales of days to weeks
[35, 11, 24]. They analysed the atrial effective refrac-
tory period (AERP), a clinical biomarker of atrial vul-
nerability, over periods of artificially induced AF and
looked at changes relative to baseline along with recov-
ery rates post pacing. AERP is known to increase in
the right atria with age [40] but shortens when in AF.
From these studies, we set α, the episode vulnerabil-
ity saturation rate, to be 52, corresponding to a time
period of 1 week [34] and β, the episode vulnerability
relaxation rate to 182.5, corresponding to a maximum
relaxation period of 2 days [35].
For the parameters governing the recovery function
R(t), we chose to estimate these based on intuition of
the AF remodelling process. We set the peak recov-
ery rate ρ0 as 0.5 seconds, which we assume to be the
shortest possible duration of an AF episode - this cor-
responds to the fastest possible recovery time from AF
of a (new born) patient in perfect health. The decay
rate of the natural AF recovery function, λ was de-
rived on the basis that, from Rage = 0.5 at t = 0, a
typical episode of a 50 year old patient would be on
the order of 14.4 minutes in duration (1% of a day).
This parameter would then be λ = log(840 × 2)/50;
in our simulation, we used a slightly larger value of
λ = 1.2× log(840)/50.
Finally, for the episode-dependent recovery rate
Repi(t), we assume that the degradation rate µ follows
the saturation rate of episode-dependent vulnerability,
α, and that the relaxation rate ν similarly follows the
corresponding relaxation, β in the vulnerability func-
tion. For the boost factorB (the overshoot above base-
line immediately after an episode terminates), we set
this to 1, which exactly reflects the decreased ampli-
tude in recovery rate from baseline due to the present
episode of AF.
4 Model Outputs
4.1 General remarks
The primary output of simulations of the model dy-
namics are patient trajectories. Each run generates a
series of AF episodes over several decades; typically
we see gradual progression of AF from paroxysmal to
permanent. These synthetic data differ from existing
clinical AF data: real-world AF ECGs are sampled at
several kilohertz over short monitoring periods from
hours to months, whilst our data simplifies the ECG
in to sequences of binary AF/sinus rhythm episodes.
The theoretical resolution of the model is dictated by
the shortest episode generated by the model parame-
ters.
We stress that the model parameters used are the
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Figure 3: Time series of the progression. A sample path is visualized by the red line, and from top to bottom:
(a) Binary signal whether the patient is in an AF episode, (b) the fraction of the time in AF episodes per day,
(c) the fraction of the time in AF episode per week, (d) the fraction of the time in AF episode per month. In
(b-d) 9 other sample paths are plotted in grey lines in order to illustrate the distribution induced by intrinsic
stochasticity. Inset: the progression of AF episode frequency and duration at time points in the simulation.
same for all simulated patients. Each virtual patient
has characteristics identical to the population average.
Thus, our model does not capture heterogeneity in
those parameters. A systematic analysis of the full pa-
rameter space is beyond the scope of the present work,
but below we highlight a number of data which hint
at the range of possible trajectories that this model
generated. It should be noted that while the parame-
ters as listed in Table 1 are the same for all subjects
in the model, different runs of the simulation will lead
to different sequences of AF/SR episodes. This het-
erogeneity comes from the inherent randomness of the
initiation and termination dynamics in the model.
Results reported below are from simulations of 5000
independent patients. On each simulation run, the
patient lives to age 100 years, develops AF at some
point and is found to enter permanent AF in their
lifetime. This is not an accurate reflection of reality,
of course, but this allows us to analyse the different
patient trajectories as a consequence of both long- and
short-term remodelling.
4.2 Patient trajectories and AF pro-
gression
The top left panel of Fig. 3 illustrates a sample time
series plotted over a 30-year time span. For any point
in time the patient is either in AF or in sinus rhythm;
episodes of AF are highlighted in red. In this example,
an initial period of quiescence gives way to a sequence
of AF episodes of increasing frequency and duration.
As can be seen on the magnification on the right-hand
side of the figure, where each time series represents
a single month, there are many short and clustered
episodes which may not be visible over the longer time-
scale view. These eventually become longer in dura-
tion until finally the patient remains in AF constantly
until death (not shown).
The red (dark) curves in panels (b)-(d) of Fig. 3 we
show the daily, weekly, and monthly AF burden of the
patient trajectory shown in panel (a). Following stan-
dard conventions [31, 41], burden is here defined as
the fraction of time spent in AF during a given obser-
vation window. To illustrate the variability of model
outcomes panels (b)-(d) depict 9 other sample paths
(light grey). AF burden shows a monotonic increasing
trend. Naturally the patient-to-patient variance re-
duces for longer observation windows (monthly versus
daily).
Using the parameter set in Table 1, we find that all
patients develop paroxysmal AF at some point, and
that they eventually enter permanent AF before the
endpoint of the simulation at age 100.
The model then allows us to simulate population
statistics for the age at which patients develop parox-
ysmal AF (‘event 1’) and for the time at which they
transition into permanent AF (‘event 2’). These are
shown in Fig. 4 (panels (a) and (b)), along with
statistics of the time that elapses between the on-
set of paroxysmal and permanent AF (panel (c)). It
seems reasonable to assign a minimum threshold which
would prompt a patient to present themselves for clin-
ical diagnosis (assuming symptomatic AF). We set
this threshold as an AF episode of duration greater
than 14.4 minutes (1% of a day). The model results
show that the first episode of AF lasting longer than
the threshold typically occurs when patients are aged
around 44-48 years, which may be perceived as earlier
than recorded in the literature [33, 37, 38, 39]. Patients
subsequently progress to permanent AF over a period
of 28-32 years (panel (c)). A potential interpretation
of these results is discussed in Section 5.
4.3 Behaviour after onset of paroxys-
mal AF
We now turn to a discussion of model outputs in a
form that may be clinically relevant. In our model we
assume that the starting point of a patient’s clinical
trajectory is the time at which they develop parox-
ysmal AF. Given the intrinsic stochasticity, this time
point will vary from patient to patient, as indicated in
panel (a) of Fig. 4.
For any one patient we can use the time at which
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Figure 4: Distributions of age at which paroxysmal AF
sets it (panel (a)), age at which permanent AF sets in
(panel (b)), and the time elapsed between these two
events (panel (c)). Data were generated from 5000
independent simulation runs of the model.
they enter paroxysmal AF as a reference time to follow
their future progression. Data are shown in 5; the
horizontal axes in the top panels of the figure indicate
time after the onset of paroxysmal AF.
In the top left panel of Fig. 5, annual AF burden
is shown. The burden increases from near zero to
one, representing the increase in the proportion of time
spent in AF as the condition progresses. Each point
on the curve represents the mean burden over 5000
simulated patients.
In the lower-left part of the figure we shown his-
tograms of AF burden at the 15 time points indicated
in the top-left panel. The numbers in the smaller
panels refer to the number of years since the onset
of paroxysmal AF. At initial times after the onset of
paroxysmal AF the burden shows a unimodal distri-
bution, and over the following 17 years the burden in-
creases for some patients while remaining low for oth-
ers producing a left skewed distribution. Around year
19 there is a shift towards a higher burden and the dis-
tribution becomes more uniform, indicating that those
patients that previously had low burden are now ex-
periencing the effects of remodelling. By year 21these
effects are evident in even more patients and the dis-
tribution becomes right skewed. Finally over years
24 − 37 all patients experience the effects of remod-
elling and progress to permanent AF indicated by the
distribution tending to a burden of 1.
The right-hand side of Fig. 5 shows the total num-
ber of episodes per year (top panel) for the same
dataset, along with detailed breakdowns of the pop-
ulation statistics in the lower right-hand panels. The
number of episodes per year rises sharply and peaks at
around 20 years after the onset of paroxysmal AF, and
then gradually decreases. This reflects the observation
that AF episodes begin intermittently, and become
more frequent as structural remodelling increases vul-
nerability and decreases recovery rate. Consequently
the episode durations lengthen and the inter-episode
times shorten, so the number of episodes is reduced
though the time spent in AF (AF burden) increases
(left-hand panels of Fig. 5).
Initially the number of episodes experienced per year
follows a unimodal distribution, with a peak at low
numbers. The pace with which AF progresses in differ-
ent virtual patients varies considerably; some will still
have infrequent episodes so a low number of episodes
per year, others will have experienced a moderate
degree of re-modelling and will have many very fre-
quent episodes. A third group will have experienced
substantial structural re-modelling and so they have
fewer episodes of longer duration. This leads to the
broad distribution at around 17 years after the onset of
paroxysmal AF. Eventually all patients will progress
to permanent AF and therefore have fewer episodes
(19-27 years after threshold). Finally AF is perma-
nent, i.e. there is one continuous episode, and then
the centre of the distribution moves towards 1 single
episode per year.
4.4 Behaviour prior to onset of perma-
nent AF
We now change perspective and look at patient pro-
gression relative to the point in time at which they de-
velop permanent AF. As discussed, different patients
can progress differently after the onset of paroxysmal
AF, and there will be considerable variation of the time
at which they enter permanent AF. To allow for the
identification of potential patterns that can determine
progression to permanent AF, we have replotted the
model outputs in Fig. 6. Time is now defined relative
to the point at which permanent AF sets in, the hori-
zontal axis in the top panels now depict time until the
onset of permanent AF. The left-hand panel shows the
annual AF burden, for the time leading up to the mo-
ment of transition to permanent AF, the panels on the
right show data for the number of episodes experienced
per year.
From the left-hand panels in Fig. 6 we can see that
the annual burden begins to increase very slowly until
16 years prior to transition to permanent AF. At that
point, patients start to progress at different speeds
causing the distribution to become more unimodal
(years 14− 12 prior to transition). By 10 years before
transition the patients are experiencing fairly high bur-
den, which continues to gradually increase until they
enter permanent AF.
Examining the right-hand panels in 6 one sees that
the number of episodes at 17 years prior to transition
has noticeably increased but the corresponding burden
(left-hand panel) is still low. This indicates that there
are many short episodes - and we know that these are
particularly unlikely to be picked up clinically simply
due to timing. The number of episodes continues to
increase and at 14 years prior to transition the dis-
tribution for the number of episodes becomes more
unimodal and symmetrical (ignoring a peak at zero
episodes, reflecting patients who have not yet entered
AF). The distribution shows a wide range in the num-
ber of episodes, with the corresponding burden also
starting to increase. This illustrates that some people
are experiencing the effects of short-term remodelling,
and having many clustered episodes. At 12 years be-
fore transition we see that most patients have many
episodes, but burden still follows a relatively normal
distribution. This indicates that some patients are ex-
periencing the effects of long-term re-modelling and
the duration of the individual episodes are increasing,
while other patients are only experiencing the effects
8
P






	



 
D
is
tr
ib
u
ti
o
n
B
0 1
Axes & Scales
0 20 40
0
0.5
1
Time (years)
A
n
n
u
al
 b
u
rd
en
115 8
1614 17 19
2421 27 29
3331 35 37
0 20 40
0
500
1000
Time (years)N
u
m
b
er
 o
f 
E
p
i.
 i
n
 a
 y
ea
r
P
ro
b
ab
il
it
y
 
D
is
tr
ib
u
ti
o
n
Numbers
0 1000
Axes & Scales
115 8
1614 17 19
2421 27 29
3331 35 37
Figure 5: Left: Top panel shows annual AF burden after patient has entered paroxysmal AF. Horizontal axis
indicates time elapsed since onset of paroxysmal AF. The mean of 5000 simulation runs is indicated as solid line,
grey area shows the standard deviation. Smaller panels at the lower left show distribution of burdens across the
patient population at the indicated points in time (years after onset of paroxysmal AF). Right: Analogous data
for the number of AF episodes experienced in a moving window of 12-months duration.
of short-term re-modelling and although they experi-
ence many episodes they are of short duration. From
6 years until the transition to permanent the number
of episodes decreases as the duration increases, until
eventually the burden is 1 and the patient remains in
AF.
5 Discussion
In this study we have presented an individual-based
model of AF progression. The model operates at pa-
tient level and operates a coarse-grained description of
their progression through the different stages of AF.
The fundamental variable of the model is the current
AF status of the patient, being either in AF or in si-
nus rhythm. The transitions between these states are
governed by history-dependent activation and termi-
nation rates, respectively. These rates are constructed
to retain some key features of the physiology and bio-
physics of AF; in particular activation and termina-
tion rates both include terms describing acute elec-
trical and structural remodelling. If a patient has
a history of AF they are more likely to initiate fur-
ther episodes, and these have a reduced probability
to terminate. Other factors we include are a baseline
vulnerability and age-dependent factors. The compo-
nents related to age include co-morbidities which may
develop over time, although we do not model these
in detail. Our model builds on the conceptual frame-
work proposed by Heijman et al [12] and we remark
that this conceptual model discusses only AF initia-
tion and maintenance, but does not explicitly detail
AF termination.
The formulation of our model is based on reaction
kinetics with transitions between states that are mod-
ulated by the activation and recovery functions. This
type of approach has been widely used in other areas
(for example to describe the state of ion channels in
cardiac cells), and yields behaviours that are broadly
consistent with experimental observation. In the case
of our model, we argue that it is reasonable to as-
sume that patients with AF will transition between
SR and AF states, and that the transition rates are
affected by age and remodelling. The functional form
of our age/co-morbidity-related vulnerability is con-
sistent with the incidence curves reported in clinical
studies [33, 38]. Where possible, we have chosen pa-
rameters based on evidence from the literature (Table
1). However, in a real patient we would expect some
parameters such as the triggering rate to be variable
rather than fixed as in the current model. We have also
implicitly included the effects of co-morbidities within
our description of vulnerability, which may not nec-
essarily be age-correlated. Separating out the effects
of co-morbidities in the vulnerability would allow us
to investigate the progression of lone AF compared to
other patient groups [42]. We expect that future stud-
ies will address these extensions of the model.
From the model outputs, we have analysed the typ-
ical disease progression of a virtual patient generated,
9









ff
 
D
is
tr
ib
u
ti
o
n
fiflffi !
0 1
Axes & Scales
1721 19
1516 14 13
1012 8 7
56 3 1
P
ro
b
ab
il
it
y
 
D
is
tr
ib
u
ti
o
n
Numbers
0 1000
Axes & Scales
40 20 0
0
0.5
1
T"#$ %& '()*+,-./ 23567 89:;<=>
A
n
n
u
al
 b
u
rd
en
40 20 0
0
500
1000
?@AC DE FGHIJKLMN OQRSU VWXYZ[\
N
u
m
b
er
 o
f 
E
p
i.
 i
n
 a
 y
ea
r
1719
1516 14 13
1012 8 7
56 3 1
21
Figure 6: (Left panel) Burden before patient goes into the permanent episode. (Right panel) Number of episodes
before the patient goes into the permanent episode. In both panels we present the mean of the random variables
(solid black) and mean ± 1 standard deviation (grey area) at the top, and at the bottom we measure the
distributions of the random variables at 15 sampled time t = [21, 19, 17, 16, 15, 14, 13, 12, 10, 8, 7, 6, 5, 3, 1] years
before the permanent episode.
and we have characterised the statistics derived from
an idealised cohort of this population-averaged pa-
tient. In particular we report data relating to AF bur-
den and the number of episodes experienced per year
from the onset of paroxysmal AF forward. Secondly we
have studied population statistics during the build-up
to developing permanent AF. We did not study persis-
tent AF in detail within the present work, other than
to define the diagnosis threshold; the ability to predict
progression to persistent AF would be of further clin-
ical interest, given the difficulty of making accurate
diagnoses from limited clinical monitoring windows.
The results from the model appear to show that
the first episode with a duration greater than 14.4
minutes, our diagnosis threshold for onset of parox-
ysmal AF, starts earlier in the patient’s life than re-
ported in the literature [33, 38]. However, it must be
noted that the model records all events, while in real-
ity these events may be asymptomatic, and therefore
remain undiagnosed and therefore undocumented for
many years [43]. As a consequence of the recording
of asymptomatic events prior to clinical diagnosis, the
time taken to transition to permanent AF (Fig. 4(c))
may appear to be overly long. The follow-up period
in published studies on the transition to permanent
AF (e.g. [44, 45]) are of a duration of between 1 and 5
years or up to 30 years in studies of lone-AF (e.g. [42]),
and include patients in both paroxysmal and persistent
states at recruitment, so direct comparison with the
present model result is challenging. However if we con-
sider the age of transition of the patient to permanent
AF, see Fig. 4(b), this does reflect findings in the liter-
ature that age is an independent predictor of chronic
AF (both persistent and permanent) and that the risk
associated with age increases beyond the age of 74 [5].
Additionally, this model takes no account of any med-
ical interventions where the transition to permanent
AF may be affected by different treatment strategies.
Combining these results with models, such as Lord et
al. [10], that capture the longer-term impacts of med-
ical interventions on a healthcare system may provide
insights into when different treatment strategies are
best applied along the progression trajectory.
We stress that the model as it stands is of a stylised
nature. While model parameters are chosen in agree-
ment with existing clinical literature, we have made
no attempt at validating the model outcome against
real-world patient data. We do believe however that
models of the type we propose here are placed some-
where between detailed mechanistic approaches and
large-scale epidemiological studies, provide a promis-
ing way forward in integrating modelling of AF. We
also note that analogous approaches are indeed possi-
ble for other diseases which progress through different
stages [46, 47, 48].
Now that a basic model is in place future work may
focus on extending and refining it. Elements to in-
corporate in the future may include a more detailed
breakdown of AF triggers, patient vulnerability and
the recovery rate. This would ultimately have to be in-
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formed by the outputs of mechanistic models. Further
important aspects include patient-to-patient variation
of the underlying parameters, and ultimately the mod-
elling of intervention techniques such as rhythm or rate
control [49] At the other end, comparison and valida-
tion against long-term clinical cohort data would be
desirable.
If progress can be made along these lines, one
may hope that the intermediate modelling approach
we propose here will ultimately establish a link be-
tween small-scale mechanistic models and large-scale
epidemiological data. Properly validated individual-
based models would ultimately contribute to the de-
velopment of computer-based personalised medicine,
and targeted pharmacological or surgical intervention.
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A Further details of the simulation al-
gorithm
Simulation of the model generates sample paths, char-
acterised by an alternating series of episode initiation
and termination times. We here briefly describe how
these are obtained.
A.1 Activation of episodes
Assume that the individual is in sinus rhythm at time
t, i.e. S(t) = 0. Its current vulnerability and its re-
covery rate are known from the subject’s prior history.
The next step of the simulation is now to find the time
∆t until the onset of the next episode. The statistics
of ∆t are governed by the time evolution of V from
time t forward.
The subject is not in AF at time t, and so until the
next episode sets in the time-dependence of vulnera-
bility is given by (t′ > t)
V (t′) = V0 + Vage(t
′) + Vepi(t
′). (9)
The waiting time until the next episode, ∆t, is then
governed by the following cumulative probability dis-
tribution
Pr(∆t ≤ T ) = 1− exp
(
−
∫ t+T
t
dt′
V (t′)
τ
)
(10)
Drawing ∆t from this distribution is non-trivial, and
so we adopt a trick. While the onset of an episode
in the clinic can obviously not be attributed to one
unique the component to V (i.e. either to V0, Vage
or Vepi) we formally treat these as separate events in
the simulation. I.e. we draw on waiting time, ∆t1 to
an episode triggered with constant rate V0/τ , another
waiting time ∆t2 generated using Vage/τ , and another
(∆t3) based on Vepi/τ . How this is done in practice
is explained below. We then use the shortest of these
three times, ∆t = min{∆t1,∆t2,∆t3}. This faithfully
reproduces the statistics governed by the total rate,
i.e. that of Eq. (10).
Simulation time is then advanced to t+∆t, the re-
covery rates are forward integrated, and an episode is
activated at t+∆t (i.e. we set S = 1).
It remains to explain how to generate waiting times
until events triggered by the above three rates.
Given that V0/τ is constant the distribution of wait-
ing times for events follows an exponential distribution
with parameter V0/τ . This can be sampled directly
setting ∆t1 = −
τ
V0
ln U1, where U1 is a random vari-
able drawn uniformly from the interval (0, 1].
To construct ∆t2, one plugs in Vage(t
′) =
V1/[τ (1 + exp [−(t
′ − tc)/td])]. Integration gives
Pr(∆t2 ≤ T )
= 1− exp
[
−
V1td
τ
log
(
e(t+T )/td + etc/td
et/td + etc/td
)]
. (11)
A sample of ∆t2 can then be obtained by drawing a
uniform random number U2 from the unit interval, and
by solving
exp
[
−
V1td
τ
log
(
e(t+∆t2)/td + etc/td
et/td + etc/td
)]
= U2. (12)
This can be done in explicit form.
Finally we construct ∆t3, using the same idea. We
have Vepi(t
′) = [V (t)− V1(t)− V0] exp (−β(t
′ − t)) us-
ing Eq. (3), and keeping in mind that the subject is
not in AF. After integration we see that ∆t3 can be
obtained from setting
exp
[
−
V (t)− V1(t)− V0
τβ
(
e−βt − e−β(t+∆t3)
)]
= U3.
(13)
Again, this can be inverted in explicit form when
U3 > exp
[
−
V (t)− V1(t)− V0
τβ
e−βt
]
, (14)
and we define ∆t3 →∞ otherwise.
A.2 Termination of episodes
Now assume the subject is in AF at time t. The al-
gorithm proceeds by drawing a time ∆t to recovery.
The recovery rate for t′ > t follows the exponential
law R(t′) = R(t)e−µ(t
′
−t) during an episode, and so
we can determine ∆t <∞ from
exp
[
−R(t)
µ
(
e−µt − e−µ(t+∆t)
)]
= U, (15)
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when
U > exp
[
−R(t)
µ
e−µt
]
, (16)
and ∆t→∞ otherwise. with a uniform random num-
ber U drawn from the unit interval.
Once ∆t is drawn, activation and recovery rates are
integrated forward until t+∆t, and the episode is ter-
minated (S(t+∆t) = 0). The algorithm then proceeds
as described in the previous section.
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